Meeting Minutes: Drug Formulary Committee - DRAFT

Date & Time: October 10, 2018, 5:30-9 PM
Minutes prepared by: Hind Douiki and Dave Hoang
Location: Elmer Andersen Building, Room 2370, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members absent: Al Heaton, R.Ph.; Margaret Artz, R.Ph., Ph.D.
- DHS staff present: Jeff Schiff, M.D., MBA; Chad Hope, Pharm.D.; Dave Hoang, Pharm.D., MBA; Sharon Feinstein-Rosenblum Pharm.D; Gabe Johnson (pharmacy student)
- Others in attendance: Hind Douiki, Pharm.D.; Ariane Casey, Pharm.D.

Report of the Chair

No new report

Approval of Minutes

Minutes from the May 2018 meeting were reviewed, amended and approved.

Old Business

New Specialty Drugs for Continued PA

- The committee discussed Tremfya and recommended to the department by a unanimous vote that Tremfya remain on PA.

New Business

New Specialty Drugs for Continued PA

- The committee discussed Trogarzo and recommended to the department by a unanimous vote that Trogarzo remain on PA, with deletion of the examples of unacceptable toxicity in the renewal criterion.
- The committee discussed Idhifa and recommended to the department by a unanimous vote that Idhifa remain on PA, with deletion of the examples of unacceptable toxicity in the renewal criterion.
The committee discussed Erleada and recommended to the department by a unanimous vote that Erleada remain on PA, with the addition of “prostate cancer” in the first bullet and deletion of the examples of unacceptable toxicity in the renewal criterion.

The committee discussed Symdeko and recommended to the department by a unanimous vote that Symdeko remain on PA.

The committee discussed Bonjesta and recommended to the department by a unanimous vote that Bonjesta remain on PA using existing criteria. Bonjesta be re-reviewed at a future DFC meeting when information on OTC doxylamine coverage is available.

The committee discussed Noctiva and recommended to the department by a unanimous vote that Noctiva remain on PA, with deletion of “voiding ≥ 2 times per night confirmed by a 24-hour urine collection” in the first bullet.

The committee discussed Rhopressa and recommended to the department by a unanimous vote that Rhopressa remain on PA, with trial and failure of a prostaglandin inhibitor AND a beta-adrenergic antagonist.

The committee discussed Jynarque and recommended to the department by a unanimous vote that Jynarque remain on PA using existing criteria. Jynarque will be re-reviewed at a future DFC meeting when more information about its place in therapy becomes available.

The committee discussed Crysita and recommended to the department by a unanimous vote that Crysita remain on PA, with deletion of the examples of unacceptable toxicity in the renewal criterion.

The committee discussed Lonhala Magnair and recommended to the department by a unanimous vote that Lonhala Magnair remain on PA, with change in quantity limit for starter kit from 30 days to 1 year.

### New Drugs for Continued PA

The committee discussed Seebri Neohaler and recommended to the department by a unanimous vote that Seebri Neohaler remain on PA.

### Existing Specialty Drugs for Continued PA

The committee discussed Imbruvica and recommended to the department by a unanimous vote that Imbruvica remain on PA, with deletion of the examples of unacceptable toxicity in the renewal criterion.

### Adjournment

Dave stated that the next DFC meeting will likely take place during the week of December 11, 2018 and that the January meeting will be PDL-related.

The meeting was adjourned at 7:44 PM Central Time.